Abstract: A method is described for producing magnolol, or a derivative or analogue thereof. The method includes obtaining MOM ether of 5,5?-diallylbiphenyl-2,2?-diol or a derivative or analogue thereof and subsequently converting the MOM ether of 5,5?-diallylbiphenyl-2,2?-diol into magnolol or a derivative or analogue thereof.

Abstract: The invention relates to nanotubes and processes for making them and intermediates of a drug moiety or its derivative/s as a structural moiety with side chain/s capable of promoting self aggregation. The side chain/s are mono or a multiple of alkyl chain/s that are substituted or unsubstituted capable of creating self aggregating assemblies. A p-amino benzoic acid (PABA) moiety or derivative as a structural moiety of 4-alkylamido-N-pyridin-2yl-benzamide with a lauric or stearic side chain. 4-alkylamido-N-pyridin-2yl-benzamide and 4-Amino-N-pyridine-2 yl-benzamide, N-(Pyridine-2-yl)-4-dodecanamido-benzamide and N-(Pyridin-2-yl)-4-stearamidobenzamide are intermediates useful for in vivo Conjugation of an active ingredient, illustrated by Rhodamine B. With Rhodamine B as an active ingredient, nano-tubes prepared with lauric side chain, which show red fluorescence and is useful for in vivo tracking.

Abstract: A method is described for producing magnolol, or a derivative or analogue thereof. The method includes obtaining MOM ether of 5,5?-diallylbiphenyl-2,2?-diol or a derivative or analogue thereof and subsequently converting the MOM ether of 5,5?-diallylbiphenyl-2,2?-diol into magnolol or a derivative or analogue thereof.

Abstract: Processes for the preparation of nanopalladium (0) catalysts are disclosed. In some embodiments, the nanopalladium (0) catalysts may be reusable. In some embodiments, the nanopalladium (0) catalysts may be heterogeneous. Nanopalladium (0) catalysts may be employed for preparing coupling products by C—C bond formation through reaction of haloarenes in the presence of base. Haloarenes used in the coupling reaction may include chloroarenes that are typically unreactive. The use of heterogeneous nanopalladium catalyst may preclude the presence of trace amounts of palladium in the final coupling product.

Abstract: A diterpene derivative compound, having the formula I, II, or III, compositions, and therapeutic compositions containing the compounds are disclosed. Also disclosed are methods for treating an inflammatory disorder by providing an inflammatory inhibiting amount of the compound as well as methods for obtaining the compound.